Benchmark prior transactions, bonds, loans or company profiles using over 300 credit metrics.

Comparables

AI transcripts & instant analysis, making earnings season easier than ever.

Earnings

A full suite of ESG data and analysis. Built for your workflow

Spot undervalued credits and potential future restructurings with our purpose-built tools.

Distressed and Restructuring

We use AI to aggregate newsflow from 2,000 sources, and deliver it to your inbox quicker than anyone else.

News

Full Financial profiles with 3 statements, KPIs, segment splits & credit metrics. All traced to source documents.

Financials

New deal analysis and covenant comparison tools, understand key risks in seconds not days.

Covenants

We've successfully predicted more than 65 price sensitive events - before they happened.

Deal predictions

Say goodbye to CTRL + F with our powerful search. Thousands of documents text searchable for any keyword or phrase.

Search

Track high yield deals from issuance through to maturity, with integrated legal, credit and ESG analysis.

High Yield Bonds

Shine a light on private markets with 9fin's news and legal analysis of syndicated loans

Leveraged Loans

21st century tech and expert analysis to help CLO teams make informed decisions faster.

Structured Credit 

Find information others can't see in one of the fastest growing corners of finance

Private Credit 

Ayden Crosby

Rachel Butt

Max Frumes

Certain lenders to Better Health (fka Physician Partners) have started talks with the company as its earnings decline, 9fin sources say.

The talks with a lender group, led by Blue Owl, come as a number of healthcare providers are facing pressure on their profitability after the Centers for Medicare & Medicaid Services changed how patients with pre-existing conditions are risk scored. This change has led to lower revenues despite prevailing costs for the same care, as previously reported.

The Kinderhook Industries-backed primary care service provider had hired Evercore and Kirkland, 9fin reported in August, with lenders banding together with Davis Polk and Houlihan Lokey prior to the negotiations.

The company on 18 October saw a ratings downgrade to CCC+ from B-, as elevated operating costs squeezed its EBITDA margin to 2% in the first half of 2024, down from 8% the same period 2023, according to S&P. As of 30 June 2024, it had roughly $142.3m in cash and an $88m revolver due 2026, the credit rater said.

High medical cost ratios, capex on newly opened locations, and $7.5m annual debt amortization costs under its $750m first-lien term loan due 2028 will put the company in a free cash flow deficit until 2026, S&P said.

Still, it has no major debt maturities until 2028 and can cover expenses for the next couple of years, it said.

The company has a $600m first lien term loan and $150m incremental loan, both due 2028. 

Representatives at Better Health, Kinderhook and Blue Owl did not respond to requests for comment.

Explore our news and analysis for our latest scoops and in-depth analysis. 

🍪 Our Cookies

Better Health kicks off talks with Blue Owl-led lender group

Read all our public content for free

Recently Published

Lenders resist KKR’s co-op ban in Stepstone carve-out financing

9Questions — Ashwin Krishnan, Morgan Stanley — Opportunistic credit finds itself in the LP spotlight

European Distressed Year in Review 2024

Taking the Credit — Highlights of 2024

What are you waiting for?